Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Taiwan Advanced NanotechROCO:6797 59 Piotroski F-Score is 4 as of Jul. 14, 2026, which is 20% below its 10-year median of 5.00. GuruFocus rates ROCO:6797 with a GF Score™ of 59/100 and a GF Value™ of NT$13.40 (Fairly Valued). The stock has 4 warning signs investors should review. Among 803 Medical Devices & Instruments companies, Taiwan Advanced Nanotech ranks worse than 56.54% on this metric.
The zones of discrimination were as such:
Good or high score = 7, 8, 9
Bad or low score = 0, 1, 2, 3
Taiwan Advanced Nanotech has an F-score of 4 indicating the company's financial situation is typical for a stable company.
The historical rank and industry rank for Taiwan Advanced Nanotech's Piotroski F-Score or its related term are showing as below:
ROCO:6797'
s Piotroski F-Score Range Over the Past 10 Years
Min: 3 Med: 5 Max: 6
Current: 4
During the past 9 years, the highest Piotroski F-Score of Taiwan Advanced Nanotech was 6. The lowest was 3. And the median was 5.
The developer of the system is Joseph D. Piotroski is relatively unknown accounting professor who shuns publicity and rarely gives interviews.
He graduated from the University of Illinois with a B.S. in accounting in 1989, received an M.B.A. from Indiana University in 1994. Five years later, in 1999, after earning a Ph.D. in accounting from the University of Michigan, he became an associate professor of accounting at the University of Chicago.
He wanted to see if he can develop a system (using a simple nine-point scoring system) that can increase the returns of a strategy of investing in low price to book (referred to in the paper as high book to market) value companies.
What he found was something that exceeded his most optimistic expectations.
Buying only those companies that scored highest (8 or 9) on his nine-point scale, or F-Score as he called it, over the 20 year period from 1976 to 1996 led to an average out-performance over the market of 13.4%.
Even more impressive were the results of a strategy of investing in the highest F-Score companies (8 or 9) and shorting companies with the lowest F-Score (0 or 1).
Over the same period from 1976 to 1996 (20 years) this strategy led to an average yearly return of 23%, substantially outperforming the average S&P 500 index return of 15.83% over the same period.
Taiwan Advanced Nanotech Piotroski F-Score Related Terms
Taiwan Advanced Nanotech Piotroski F-Score Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ROCO:6797 vs ABT, SYK, MDT: Piotroski F-Score Comparison
For the Medical Devices subindustry, Taiwan Advanced Nanotech's Piotroski F-Score, along with its competitors' market caps and Piotroski F-Score data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Taiwan Advanced Nanotech Piotroski F-Score vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Taiwan Advanced Nanotech's Piotroski F-Score distribution charts can be found below:
* The bar in red indicates where Taiwan Advanced Nanotech's Piotroski F-Score falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
*Note: If the latest quarterly/semi-annual/annual total assets data is 0, then we will use previous quarterly/semi-annual/annual data for all the items in the balance sheet.
Profitability
Question 1. Return on Assets (ROA)
Net income before extraordinary items for the year divided by Total Assets at the beginning of the year.
Score 1 if positive, 0 if negative.
Taiwan Advanced Nanotech's current Net Income (TTM) was -226.6.
==> Negative ==> Score 0.
Question 2. Cash Flow Return on Assets (CFROA)
Net cash flow from operating activities (operating cash flow) divided by Total Assets at the beginning of the year.
Score 1 if positive, 0 if negative.
Taiwan Advanced Nanotech's current Cash Flow from Operations (TTM) was -21.0.
==> Negative ==> Score 0.
Question 3. Change in Return on Assets
Compare this year's return on assets (1) to last year's return on assets.
Taiwan Advanced Nanotech's return on assets of this year was -0.16467839. Taiwan Advanced Nanotech's return on assets of last year was -0.10640227.
==> Last year is higher ==> Score 0.
Question 4. Quality of Earnings (Accrual)
Compare Cash flow return on assets (2) to return on assets (1)
Taiwan Advanced Nanotech's gearing of this year was 0.10757343. Taiwan Advanced Nanotech's gearing of last year was 0.11173044.
==> This year is lower or equal to last year. ==> Score 1.
Question 6. Change in Working Capital (Liquidity)
Compare this year's current ratio (current assets divided by current liabilities) to last year's current ratio.
Score 1 if this year's current ratio is higher, 0 if it's lower
Taiwan Advanced Nanotech's current ratio of this year was 3.03552712. Taiwan Advanced Nanotech's current ratio of last year was 5.74713785.
==> Last year's current ratio is higher ==> Score 0.
Question 7. Change in Shares in Issue
Compare the number of shares in issue this year, to the number in issue last year.
Score 0 if there is larger number of shares in issue this year, 1 otherwise.
Taiwan Advanced Nanotech's number of shares in issue this year was 30.561. Taiwan Advanced Nanotech's number of shares in issue last year was 30.732.
==> There is smaller number of shares in issue this year, or the same. ==> Score 1.
Efficiency
Question 8. Change in Gross Margin
Compare this year's gross margin (Gross Profit divided by sales) to last year's.
Score 1 if this year's gross margin is higher, 0 if it's lower.
Taiwan Advanced Nanotech's gross margin of this year was -0.49101203. Taiwan Advanced Nanotech's gross margin of last year was -0.15213244.
==> Last year's gross margin is higher ==> Score 0.
Question 9. Change in asset turnover
Compare this year's asset turnover (total sales for the year divided by total assets at the beginning of the year) to last year's asset turnover ratio.
Score 1 if this year's asset turnover ratio is higher, 0 if it's lower
Taiwan Advanced Nanotech's asset turnover of this year was 0.11218446. Taiwan Advanced Nanotech's asset turnover of last year was 0.11032409.
==> This year's asset turnover is higher. ==> Score 1.
Evaluation
Piotroski F-Score
=
Que. 1
+
Que. 2
+
Que. 3
+
Que. 4
+
Que. 5
+
Que. 6
+
Que. 7
+
Que. 8
+
Que. 9
=
0
+
0
+
0
+
1
+
1
+
0
+
1
+
0
+
1
=
4
Good or high score = 7, 8, 9
Bad or low score = 0, 1, 2, 3
Taiwan Advanced Nanotech has an F-score of 4 indicating the company's financial situation is typical for a stable company.
Taiwan Advanced Nanotech (ROCO:6797) has a Piotroski F-Score of 4 as of Jul. 14, 2026. The Piotroski F-score grades a company's business operating strength from 0-9. View historical data on Taiwan Advanced Nanotech and its competitors. This is 20% below median its historical median of 5.00. Over the past decade, Taiwan Advanced Nanotech's Piotroski F-Score has ranged from 3.00 to 6.00. According to the industry distribution chart, Taiwan Advanced Nanotech ranks #454 out of 803 companies in the Medical Devices & Instruments industry, placing it in the top 56.5%.
Is Taiwan Advanced Nanotech's Piotroski F-Score too high?
Taiwan Advanced Nanotech's current Piotroski F-Score of 4 is 20% below median its 10-year median of 5.00. Over the past 10 years, this metric has ranged from a low of 3.00 to a high of 6.00. The Medical Devices & Instruments industry median Piotroski F-Score is 5.00. Taiwan Advanced Nanotech's value of 4 is 20% below this industry median. Based on the distribution chart, Taiwan Advanced Nanotech ranks #454 out of 803 companies in the Medical Devices & Instruments industry, which is below the industry midpoint. Overall, Taiwan Advanced Nanotech has a GF Score™ of 59/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Taiwan Advanced Nanotech's Piotroski F-Score compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, Taiwan Advanced Nanotech ranks #454 out of 803 companies for Piotroski F-Score. This places Taiwan Advanced Nanotech in the lower half of its industry. The industry median Piotroski F-Score is 5.00. Taiwan Advanced Nanotech's value of 4 is 20% below this benchmark. Historically, Taiwan Advanced Nanotech's own Piotroski F-Score has ranged from 3.00 to 6.00 over the past decade. While the company's 10-year median is 5.00 vs. the industry median of 5.00, Taiwan Advanced Nanotech has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Piotroski F-Score for a Medical Devices & Instruments company?
The median Piotroski F-Score among Medical Devices & Instruments companies is 5.00, based on 803 companies in the industry. Companies in the top quartile (top 25%) have a Piotroski F-Score significantly above this median, while those in the bottom quartile fall well below. However, Piotroski F-Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Taiwan Advanced Nanotech's current Piotroski F-Score of 4 is 20% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Piotroski F-Score mean?
A high Piotroski F-Score can signal that a stock is expensive relative to its fundamentals. The Piotroski F-score grades a company's business operating strength from 0-9. View historical data on Taiwan Advanced Nanotech and its competitors. For the Medical Devices & Instruments industry, the median Piotroski F-Score is 5.00 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Taiwan Advanced Nanotech's current Piotroski F-Score is 4, which is 20% below median its own 10-year median of 5.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Taiwan Advanced Nanotech stock overvalued right now?
Based on GuruFocus' analysis, Taiwan Advanced Nanotech (ROCO:6797) is currently considered Fairly Valued. The stock's GF Value™ is NT$13.40, compared to a current price of NT$13.20 — trading 1.5% below its estimated fair value. The current Piotroski F-Score is 4, which is 20% below median its 10-year median of 5.00 and 20% below the Medical Devices & Instruments industry median of 5.00. Taiwan Advanced Nanotech's overall GF Score™ is 59/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Piotroski F-Score calculated?
Piotroski F-Score is calculated from a company's financial statements. For Taiwan Advanced Nanotech (ROCO:6797), the current Piotroski F-Score is 4 as of Jul. 14, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Taiwan Advanced Nanotech (ROCO:6797) Overvalued in 2026?
Based on GuruFocus' analysis, Taiwan Advanced Nanotech stock appears to be undervalued.
The current stock price of NT$13.20 is trading 1.5% below its estimated GF Value™ of NT$13.40.
GuruFocus considers Taiwan Advanced Nanotech to be Fairly Valued.
Key valuation signals for ROCO:6797:
Piotroski F-Score: 4 (20% below median its 10-year median of 5.00)
GF Value™: NT$13.40 vs. price of NT$13.20 (1.5% below fair value)
Industry Position: 20% below the Medical Devices & Instruments median (#454 of 803)
No single metric tells the full story. See the ROCO:6797 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Taiwan Advanced Nanotech Inc is engaged in development and manufacturing of various functional nanoparticles and automated nucleic acid extraction machines and trading related businesses. With expertise in automation, buffer optimization and modification of magnetic beads, it focuses on offering customer convenient and practical solutions to advance research, life science and molecular diagnostics. It offers various products to meet the requirements of customers. The company's products include Automated Extraction Instruments; Reagent Kit; Mag Nanoparticles; and Consumables.
59GF Score
Get the complete analysis for ROCO:6797
Piotroski F-Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ROCO:6797 has been successfully added to your 
